Autres langues HBM Holdings Limited

Actions

2142

KYG4403H1002

Temps Différé Hong Kong S.E. Autres places de cotation 08:30:42 20/05/2024			Varia. 5j.	Varia. 1 janv.
1,48 ^HKD	+7,25 %		+4,23 %	-23,71 %

02/04	HBM Holdings redevient rentable en 2023	MT
28/03	HBM Holdings Limited annonce ses résultats pour l'exercice clos le 31 décembre 2023	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

HBM Holdings Returns to Profitability in 2023	02/04
Harbour BioMed Reports Full Year 2023 Financial Results	28/03
HBM Holdings Limited Reports Earnings Results for the Full Year Ended December 31, 2023	28/03
HBM Holdings Subsidiary Signs Antibody-Drug Conjugate Discovery Collaboration Deal	27/02
HBM Holdings Gets US FDA Clinical Trial Approval for Anti-Tumor Medication	24/01
Harbour BioMed Announces IND Clearance for HBM9027 in the U.S	24/01
HBM to Swing to 2023 Profit	19/01
Harbour BioMed Announces Positive Profit Alert	19/01
HBM Holdings Limited Provides Earnings Guidance for the Year Ended 31 December 2023	19/01
HBM Holdings Limited commences an Equity Buyback Plan for 76,842,891 shares, representing 10% of its issued share capital, under the authorization approved on June 8, 2023.	19/12
Harbour BioMed's Wholly-owned Subsidiary Nona Biosciences Enters into a Global License Agreement with Pfizer for HBM9033, an MSLN-Targeted Antibody-Drug Conjugate	15/12
HBM Holdings Unit Nona Biosciences Signs Licensing Deal with Seagen for Tumor Medication; Shares Fall 5%	15/12
HBM Holdings Limited Announces Results of the Phase Iii Clinical Trial, Which Demonstrated That the Efficacy in the Primary and Secondary Endpoints of Batoclimab	01/12
HBM Holdings Limited Announces Executive Changes	19/10/23
HBM Swings to Profit in H1; Shares Up 6%	29/08/23
HBM Gets US FDA Clearance to Hold Anti-Tumor Drug Trials in US	29/08/23
Harbour BioMed Announces US IND Clearance of Its First ADC Program HBM9033 in Solid Tumors	28/08/23
HBM Holdings Limited Reports Earnings Results for the Half Year Ended June 30, 2023	28/08/23
Harbour BioMed Appoints Dr. Albert R. Collinson as Independent Non-Executive Director	08/08/23
Harbour BioMed Appoints Dr. Albert R. Collinson as Independent Non-Executive Director	08/08/23

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues HBM Holdings Limited

Actions

2142

KYG4403H1002

Autres langues

Filtres